Início › Câncer de Mama › Novo México
Ensaios clínicos de Câncer de Mama em Novo México
19 estudos para Câncer de Mama estão buscando participantes em locais em Novo México.
Cidades em Novo México
Texto oficial do estudo (Inglês)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Presbyterian Medical Group, Albuquerque
RecrutandoFase 3
Idades de 18 a 100 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- e mais 3
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- The University of New Mexico, Albuquerque
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07102381A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Presbyterian Kaseman Hospital ( Site 0072), Albuquerque
- University of New Mexico Comprehensive Cancer Center ( Site 0047), Albuquerque
- Presbyterian Rust Jorgensen Cancer ( Site 0073), Rio Rancho
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07060807The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Lovelace Medical Center - Saint Joseph Square, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
- e mais 3
RecrutandoFase 3
Idades 60 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06377852A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Albuquerque
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06103864Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Santa Fe
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- New Mexico Oncology & Hematology Consultants, Albuquerque
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07214532A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Exigent Research LLC/New Mexico Oncology Hematology Consultants Ltd., Albuquerque
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT06492616A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Albuquerque
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 11 de set. de 2026 · NCT05123482A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- San Juan Oncology Associates, Farmington
RecrutandoFase 1
Idades de 18 a 55 · Mulheres · Atualizado em 9 de set. de 2026 · NCT07310420Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- University of New Mexico Cancer Center, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
- Memorial Medical Center-Las Cruces, Las Cruces
- e mais 1
RecrutandoFase 3
Idades de 18 a 60 · Mulheres · Atualizado em 2 de set. de 2026 · NCT05879926Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Presbyterian Kaseman Hospital, Albuquerque
- Presbyterian Rust Cancer Center, Rio Rancho
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de jun. de 2026 · NCT05696626De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- University of New Mexico Cancer Center, Albuquerque
RecrutandoFase 3
Idades de 50 a 70 · Todos os sexos · Atualizado em 23 de abr. de 2026 · NCT04852887SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
- University of New Mexico, Albuquerque
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 7 de abr. de 2026 · NCT06896474Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- e mais 3
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 17 de mar. de 2026 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Albuquerque
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- University of New Mexico Cancer Center, Albuquerque
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 8 de out. de 2025 · NCT03418961BostonGene and Exigent Genomic INsight Study
- New Mexico Cancer Center, Albuquerque
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 17 de fev. de 2025 · NCT06272864Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.